- Home
- LBRDA vs ROIV Comparison
LBRDA vs ROIV Comparison
Compare LBRDA & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBRDA
- ROIV
- Stock Information
- Founded
- LBRDA 2014
- ROIV 2014
- Country
- LBRDA United States
- ROIV United Kingdom
- Employees
- LBRDA N/A
- ROIV N/A
- Industry
- LBRDA Cable & Other Pay Television Services
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- LBRDA Telecommunications
- ROIV Health Care
- Exchange
- LBRDA Nasdaq
- ROIV Nasdaq
- Market Cap
- LBRDA 9.5B
- ROIV 8.4B
- IPO Year
- LBRDA N/A
- ROIV N/A
- Fundamental
- Price
- LBRDA $59.49
- ROIV $12.30
- Analyst Decision
- LBRDA Strong Buy
- ROIV Strong Buy
- Analyst Count
- LBRDA 2
- ROIV 10
- Target Price
- LBRDA $81.00
- ROIV $17.33
- AVG Volume (30 Days)
- LBRDA 111.8K
- ROIV 4.2M
- Earning Date
- LBRDA 11-01-2024
- ROIV 08-08-2024
- Dividend Yield
- LBRDA N/A
- ROIV N/A
- EPS Growth
- LBRDA 1.43
- ROIV N/A
- EPS
- LBRDA 5.54
- ROIV 5.65
- Revenue
- LBRDA $981,000,000.00
- ROIV $158,303,000.00
- Revenue This Year
- LBRDA $3.67
- ROIV $45.51
- Revenue Next Year
- LBRDA $1.97
- ROIV $42.29
- P/E Ratio
- LBRDA $10.76
- ROIV $2.18
- Revenue Growth
- LBRDA N/A
- ROIV 101.44
- 52 Week Low
- LBRDA $47.17
- ROIV $8.25
- 52 Week High
- LBRDA $95.08
- ROIV $13.24
- Technical
- Relative Strength Index (RSI)
- LBRDA 44.78
- ROIV 65.79
- Support Level
- LBRDA $58.52
- ROIV $11.50
- Resistance Level
- LBRDA $62.07
- ROIV $12.60
- Average True Range (ATR)
- LBRDA 1.41
- ROIV 0.35
- MACD
- LBRDA -0.43
- ROIV 0.04
- Stochastic Oscillator
- LBRDA 22.73
- ROIV 79.19
About LBRDA Liberty Broadband Corporation
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential and small to medium businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.